NCT07444710 2026-03-19
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
Clinical Trials
10 trialsNCT07286331 2026-03-11
A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)
GlaxoSmithKline
Phase 3 Not yet recruiting
NCT07463313 2026-03-11
6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2/3 Not yet recruiting
NCT07460986 2026-03-10
BEXAR
MedSIR
Phase 1/2 Not yet recruiting
NCT07441460 2026-03-02
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
NCT07300475 2026-02-13
Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients
Washington University School of Medicine
Phase 1 Not yet recruiting
NCT06594939 2026-02-04
Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
Medical College of Wisconsin
Phase 2 Not yet recruiting
NCT07370506 2026-01-29
Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
Tanta University
Phase 1/2 Not yet recruiting
NCT07341867 2026-01-14
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07321912 2026-01-08
Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Milton S. Hershey Medical Center
Phase 2 Not yet recruiting